Ein Arzt berät einen Patienten (Symbolbild).
Freitag, 11.09.2015 22:30 von | Aufrufe: 34

Capital Pro-Égaux Inc (NEX: CPE.H) announces the conclusion of a license agreement with exocad America, Inc.

Ein Arzt berät einen Patienten (Symbolbild). © TommL / Vetta / Getty Images https://www.gettyimages.de/

Canada NewsWire

MORIN-HEIGHTS, QC, Sept. 11, 2015 /CNW Telbec/ - Capital Pro-Égaux Inc. (the "Company") (NEX: CPE.H) announces that its wholly-owned subsidiary, Technique d'usinage Sinlab Inc. ("Sinlab"), has entered into a Patent License Agreement with exocad America, Inc.  As part of the agreement, Sinlab granted exocad America, Inc. a worldwide, perpetual, non-exclusive license in and to all of Sinlab's digital dentistry patents, including patents relating to its Technobar and Technoguide technologies that extends to all current resellers of exocad software, as listed on exocad.com/partners, as well as small and  medium-sized dental labs that use exocad software for their design or manufacturing processes. The terms remain undisclosed for confidentiality reasons.

The Company previously announced settlement and/or license agreements that include Biomet 3i, LLC (formerly Implant Innovations, Inc.); Delcam USA, Inc. and Delcam Holdings, Inc.; Cagenix, Inc.; Dentsply International Inc.; Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc.; Biocad Médical Inc.; Nobel Biocare USA, LLC; Nobel Biocare Procera, LLC; and 3Shape A/S.  The Company is currently pursuing its licensing program with other industry participants.  The Company cannot predict the outcome of its ongoing negotiations or of any legal proceedings it may decide to institute against those entities that fail or refuse to contract a license. The decision to take legal proceedings will be based on available information and the Company's assessment of all relevant facts and circumstances, including costs involved with such proceedings. Such costs are unpredictable and may be substantial.

Caution regarding forward-looking statements

This news release contains certain forward-looking statements regarding the Company's expectation of future events, including potential claims and the institution of legal proceedings. Such expectations are based on certain assumptions based on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could lead actual results to differ include, amongst others, factors that may impact claims and legal proceedings, such as interpretation of factual matters, time and money involved in undertaking legal proceedings, uncertainty as to the final result and other risks. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by securities laws.

About Pro-Égaux Inc.

Pro-Égaux through its wholly owned subsidiary, Technique d'usinage Sinlab Inc., is a company based in Lachenaie, Quebec, specializing mainly in the conception and design of titanium products to be used in the dental prosthesis restoration industry.

Neither NEX, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of NEX and the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


ARIVA.DE Börsen-Geflüster

Kurse

SOURCE Capital Pro-Égaux Inc.

Werbung

Mehr Nachrichten zur CAPITAL PRO EGAUX INC Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.